Development asset linked to Kailera Therapeutics in public FDA and regional records.
pharma · Obesity · Obesity With Diabetes · KLRA
Kailera Therapeutics
Kailera Therapeutics drug portfolio — 3 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Waltham, USA HQ
2024 Founded
153 Employees
Public company Type
KLRA · NYSE Ticker
Company details
- Status
- Public
- HQ
- Waltham, USA
- Founded
- 2024
- Employees
- 153
- Programs
- 7
- Drugs
- 3
- Patents
- 0
Kailera Therapeutics pipeline
Portfolio lens on 3 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Kailera Therapeutics drug portfolio — 3 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
semaglutide
Alimentary tract and metabolism (A10)US regulatory status: approved. Molecular target: Glucagon-like peptide 1 receptor.
- Target
- Glucagon-like peptide 1 receptor
- Mechanism
- Glucagon-like peptide 1 receptor agonist
-
Development asset linked to Kailera Therapeutics in public FDA and regional records.